GoodRx Holdings, Inc.

Equities

GDRX

US38246G1085

Internet Services

Real-time Estimate Cboe BZX 11:24:54 2024-03-28 am EDT 5-day change 1st Jan Change
7.205 USD +2.78% Intraday chart for GoodRx Holdings, Inc. +7.04% +7.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Markets Steady -2- DJ
GoodRx Shares Jump Following Wells Fargo Upgrade, Price Target Boost MT
Top Premarket Gainers MT
Wells Fargo Upgrades GoodRx Holdings to Overweight From Equalweight, Adjusts Price Target to $10 From $7.50 MT
Transcript : GoodRx Holdings, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:00 AM
Deutsche Bank Adjusts GoodRx Price Target to $9 From $7, Maintains Hold Rating MT
North American Morning Briefing : Stock Futures -2- DJ
Goldman Sachs Raises GoodRx Holdings' Price Target to $7.50 From $6.50, Maintains Neutral Rating MT
UBS Adjusts GoodRx Holdings Price Target to $8 From $5, Maintains Neutral Rating MT
TD Cowen Adjusts Price Target on GoodRx Holdings to $14 From $12, Maintains Outperform Rating MT
Truist Adjusts Price Target on GoodRx Holdings to $8 From $7.50, Maintains Hold Rating MT
JPMorgan Adjusts GoodRx Holdings' Price Target to $7 From $6, Maintains Neutral Rating MT
RBC Raises Price Target on GoodRx Holdings to $8 From $7, Keeps Sector Perform Rating MT
GoodRx Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GoodRx Q4 Adjusted Earnings, Revenue Gain; Sets Q1, 2024 Revenue Outlook; Approves $450 Million Share Buyback Plan MT
Transcript : GoodRx Holdings, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Earnings Flash (GDRX) GOODRX HOLDINGS Reports Q4 Revenue $196.6M, vs. Street Est of $195.9M MT
Earnings Flash (GDRX) GOODRX HOLDINGS Reports Q4 EPS $0.08, vs. Street Est of $0.07 MT
North American Morning Briefing : Fed's Preferred -2- DJ
GoodRx Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Goodrx Holdings, Inc. Provides Revenue Guidance for First Quarter 2024 and Fiscal Year 2024 CI
GoodRx Holdings, Inc. announces an Equity Buyback for $450 million worth of its shares. CI
Tranche Update on GoodRx Holdings, Inc.'s Equity Buyback Plan announced on February 28, 2022. CI
GoodRx Holdings, Inc. authorizes a Buyback Plan. CI
Leerink Partners Initiates GoodRx Holdings at Outperform Rating With $8 Price Target MT
Chart GoodRx Holdings, Inc.
More charts
GoodRx Holdings, Inc. provides a consumer-focused digital healthcare platform in the United States. It offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. It also equips healthcare professionals to find and prescribe affordable medications. It offers information and tools to help consumers compare prices and save on their prescription drug purchases. It operates a price comparison platform that provides consumers with geographically relevant prescription pricing and provides access to negotiated prices through its codes that can be used to save money on prescriptions across the United States (the prescription transactions offering). It also offers other healthcare products and services, including pharmaceutical manufacturer solutions, subscriptions, and telehealth services. Its subscription offerings provide additional benefits to consumers of its prescription transactions offering.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
7.01 USD
Average target price
8.661 USD
Spread / Average Target
+23.55%
Consensus
  1. Stock
  2. Equities
  3. Stock GoodRx Holdings, Inc. - Nasdaq
  4. News GoodRx Holdings, Inc.
  5. Citigroup Adjusts Price Target on GoodRx Holdings to $7 From $7.50, Keeps Buy Rating